Lipid-lowering effect of cordycepin (3′-deoxyadenosine) from Cordyceps militaris on hyperlipidemic hamsters and rats

Yaoxue Xuebao

Volumn 46, Issue 6, 2011, Pages 669-676

  Gao, Jian ^a   Lian, Ze Qin ^a   Zhu, Ping ^a   Zhu, Hai Bo ^a  

^a INSTITUTE OF MATERIA MEDICA   (China)

Author keywords

Cordycepin; Cordyceps militaris; Hyperlipidemia; Lipid lowering effect

Indexed keywords

CORDYCEPIN; CORDYCEPS MILITARIS EXTRACT; FENOFIBRATE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPID; LIPOPROTEIN LIPASE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLANT EXTRACT; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CORDYCEPS; DRUG EFFECT; FEMALE; HAMSTER; HYPERLIPIDEMIA; LIPID BLOOD LEVEL; LIPID DIET; MALE; MOUSE; NONHUMAN; RAT; TREATMENT DURATION; TRIACYLGLYCEROL BLOOD LEVEL;

ANIMALS; CHOLESTEROL; CHOLESTEROL, LDL; CHOLESTEROL, VLDL; CORDYCEPS; CRICETINAE; DEOXYADENOSINES; HYPERLIPIDEMIAS; HYPOLIPIDEMIC AGENTS; LIPASE; LIPIDS; LIPOPROTEIN LIPASE; MALE; MESOCRICETUS; MICE; MICE, INBRED ICR; RATS; RATS, WISTAR; TRIGLYCERIDES;

EID: 79959393843     PISSN: 05134870     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Jiamsripong P, Mookadam M, Honda T, et al. The metabolic syndrome and cardiovascular disease: part I [J]. Prev Cardiol, 2008, 11: 155-161.
2. Kashani A, Sallam T, Bheemreddy S, et al. Review of side-effect profile of combination ezetimibe and statin therapy in randomized clinical trials [J]. Am J Cardiol, 2008, 101: 1606-1613.
3. Robinson JG Should we use ppar agonists to reduce cardiovascular risk? [J]. PPAR Res, 2008, 891425.
4. Guyton JR, Bays HE. Safety considerations with niacin therapy [J]. Am J Cardiol, 2007, 99 (6A): 22C-31C.
5. Filippatos TD, Mikhailidis DP. Lipid-lowering drugs acting at the level of the gastrointestinal tract [J]. Curr Pharm Des, 2009, 15: 490-516.
6. Dou XB, Wo XD, Fan CL. Progress of research in treatment of hyperlipidemia by monomer or compound recipe of Chinese herbal medicine [J]. Chin J Integr Med, 2008, 14: 71-75.
7. Yin J, Zhang H, Ye J. Traditional Chinese medicine in treatment of metabolic syndrome [J]. Endocr Metab Immune Disord Drug Targets, 2008, 8: 99-111.
8. Tian GQ, Liang XC, Guo SS, et al. Effect of Ningzhi capsule on blood lipid spectrum in type 2 diabetes mellitus patients complicated with hyperlipidemia [J]. Chin J Integr Tradit Chin West Med, 2008, 28: 118-121.
9. Li SZ. Compendium of Materia Medica [M]. 1596.
10. Singh G, Gupta P, Rawat P, et al. Antidyslipidemic activity of polyprenol from Coccinia grandis in high-fat diet-fed hamster model [J]. Phytomedicine, 2007, 14: 792-798.
11. Warnick GR, Knopp RH, Fitzpatrick V, et al. Estimating low-density lipoprotein cholesterol by the friedewald equation is adequate for classifying patients on the basis of nationally recommended cutpoints [J]. Clin Chem, 1990, 36: 15-19.
12. Cunningham KG, Manson W, Spring FS, et al. Cordycepin, a metabolic product isolated from cultures of Cordyceps militaris (Linn.) Link [J]. Nature, 1950, 166: 949.
13. Paterson RR. Cordyceps: a traditional Chinese medicine and another fungal therapeutic biofactory? [J]. Phytochemistry, 2008, 69: 1469-1495.
14. Trigg PI, Gutteridge WE, Williamson J. The effects of cordycepin on malaria parasites [J]. Trans R Soc Trop Med Hyg, 1971, 65: 514-520.
15. de Julián-Ortiz JV, Gálvez J, Muñoz-Collado C, et al. Virtual combinatorial syntheses and computational screening of new potential anti-herpes compounds [J]. J Med Chem, 1999, 42: 3308-3314.
16. Wehbe-Janek H, Shi Q, Kearney CM. Cordycepin/hydroxyurea synergy allows low dosage efficacy of cordycepin in MOLT-4 leukemia cells [J]. Anticancer Res, 2007, 27: 3143-3146. (Pubitemid 47607537)
17. Jen CY, Lin CY, Leu SF, et al. Cordycepin induced ma-10 mouse Leydig tumor cell apoptosis through caspase-9 pathway [J]. Evid Based Complement Alternat Med, 2011, Article ID 984537.
18. Ng TB, Wang HX. Pharmacological actions of Cordyceps, a prized folk medicine [J]. J Pharm Pharmacol, 2005, 57: 1509-1519. (Pubitemid 41752265)
19. Kris-Etherton PM, Dietschy J. Design criteria for studies examining individual fatty acid effects on cardiovascular disease risk factors: human and animal studies [J]. Am J Clin Nutr, 1997, 65 (5 Suppl): 1590S-1596S.
20. Sugano M, Fujikawa T, Hiratsuji Y, et al. A novel use of chitosan as a hypocholesterolemic agent in rats [J]. Am J Clin Nutr, 1980, 33: 787-793. (Pubitemid 10077666)
21. Sundram K, Khor HT, Ong AS. Effect of dietary palm oil and its fractions on rat plasma and high density lipoprotein lipids [J]. Lipids, 1990, 25: 187-193. (Pubitemid 20135049)
22. Assmann G, Cullen P, Jossa F, et al. Coronary heart disease: reducing the risk: the scientific background to primary and secondary prevention of coronary heart disease. A worldwide view. International task force for the prevention of coronary heart disease [J]. Arterioscler Thromb Vasc Biol, 1999, 19: 1819-1824. (Pubitemid 29379910)
23. Miller M, Ginsberg HN, Schaefer EJ. Relative atherogenicity and predictive value of non-high-density lipoprotein cholesterol for coronary heart disease [J]. Am J Cardiol, 2008, 101: 1003-1008.
24. Hafidh SA, Lavie CJ, Burns BP, et al. Dyslipidemia in the metabolic syndrome: clinical implications and management [J]. Minerva Cardioangiol, 2006, 54: 215-227. (Pubitemid 43977441)
25. Eisenberg S. Lipoproteins and lipoprotein metabolism. A dynamic evaluation of the plasma fat transport system [J]. Klin Wochenschr, 1983, 61: 119-132.
26. Illingworth DR, Durrington PN. Dyslipidemia and atherosclerosis: how much more evidence do we need? [J]. Curr Opin Lipidol, 1999, 10: 383-386.
27. National Cholesterol Education Program. Second report of the expert panel on detection, evaluation and treatment of high blood cholesterol in adults (adult treatment panel II) [J]. Circulation, 1994, 89: 1333-1445.
28. Laurence L. Goodman & Gilman's The Pharmacological Basis of Therapeutics [M]. 11th ed. New York: McGraw-Hill, 2006.